|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM335073301 |
| 003 |
DE-627 |
| 005 |
20231225225032.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2021.108918
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1116.xml
|
| 035 |
|
|
|a (DE-627)NLM335073301
|
| 035 |
|
|
|a (NLM)34971839
|
| 035 |
|
|
|a (PII)S1521-6616(21)00255-2
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Cristiano, Antonio
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Evaluation of serological anti-SARS-CoV-2 chemiluminescent immunoassays correlated to live virus neutralization test, for the detection of anti-RBD antibodies as a relevant alternative in COVID-19 large-scale neutralizing activity monitoring
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 21.01.2022
|
| 500 |
|
|
|a Date Revised 21.12.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2021 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a The Spike-Receptor Binding Domain (S-RBD) is considered the most antigenic protein in SARS-CoV-2 and probably the key player in SARS-CoV-2 immune response. Quantitative immunoassays may help establish an anti-RBD Abs threshold as an indication of protective immunity. Since different immunoassays are commercial, the standard reference method for the neutralizing activity is the live Virus Neutralization Test (VNT). In this study, anti-RBD IgG levels were detected with two chemiluminescent immunoassays in paucisymptomatic, symptomatic and vaccinated subjects, and their neutralizing activity was correlated to VNT titer, using SARS-CoV-2 original and British variant strains. Both immunoassays confirmed higher anti-RBD Abs levels in vaccinated subjects. Furthermore, despite different anti-RBD Abs median concentrations between the immunoassays, a strong positive correlation with VNT was observed. In conclusion, although the SARS-CoV-2 immune response heterogeneity, the use of immunoassays can help in large-scale monitoring of COVID-19 samples, becoming a valid alternative to VNT test for diagnostic routine laboratories
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Anti-SARS-CoV-2 antibodies
|
| 650 |
|
4 |
|a COVID-19
|
| 650 |
|
4 |
|a Live virus neutralization test
|
| 650 |
|
4 |
|a SARS-CoV-2
|
| 650 |
|
4 |
|a Serological immunoassays
|
| 650 |
|
7 |
|a Antibodies, Neutralizing
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Viral
|2 NLM
|
| 650 |
|
7 |
|a Spike Glycoprotein, Coronavirus
|2 NLM
|
| 700 |
1 |
|
|a Pieri, Massimo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sarubbi, Serena
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pelagalli, Martina
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Calugi, Graziella
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tomassetti, Flaminia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bernardini, Sergio
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nuccetelli, Marzia
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 234(2022) vom: 07. Jan., Seite 108918
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:234
|g year:2022
|g day:07
|g month:01
|g pages:108918
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2021.108918
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 234
|j 2022
|b 07
|c 01
|h 108918
|